Humanwell Healthcare (600079.SH): HW201877 capsules received the notification of approval for clinical drug trials.

07/03/2025

GMT Eight

Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary, Wuhan Renfu Innovation Drug Development Center Co., Ltd. (referred to as "Innovation Drug Development Center"), has recently received the Drug Clinical Trial Approval Notice for HW201877 Capsules issued by the National Medical Products Administration. The indication applied for is inflammatory bowel disease. HW201877 Capsules are intended for clinical use in patients with inflammatory bowel disease. Currently, there are no similar products on the market in China. As of now, the cumulative research and development investment in this project by the Innovation Drug Development Center is approximately 40 million RMB.

Ningbo Menovo Pharmaceutical's subsidiary, Shakuba Qu Xie Losartan Sodium API, passed the CDE technical review.

State Administration of Foreign Exchange: As of the end of February, China's foreign exchange reserves reached 3.2272 trillion US dollars, an increase of 0.57% compared to the previous month.

Contact: contact@gmteight.com

Humanwell Healthcare (600079.SH): HW201877 capsules received the notification of approval for clinical drug trials.

RECOMMEND

American Economy: Stagflation or Recession?

Ping An Securities: Economic "stagflation" expectations are warming up, coupled with downward revisions in performance expectations. There is still pressure for further correction in the US stock market.

China Securities Co., Ltd.: The mid-term trend of revaluation of Chinese assets confidence is expected to continue. The technology growth sector is still the main driver in the mid-term.